Conscience is turning drug discovery into a team sport. We're building an open science network to collaborate across industry, academia, and the public sector; stewarding the AI-enabled computational drug discovery competition CACHE; and providing support to advance promising preclinical drug development targets in areas of market failure like rare disease, antimicrobial resistance, and pandemic preparedness.
External link for Conscience
101 College Street
Suite 700
Toronto, Ontario, CA
Conscience reposted this
Meet Ryan Merkley, CEO of Conscience—a biotech non-profit using AI and collaborative science to solve market failures in drug development. Ryan will be at the #NGBiSummit on Nov 12th at the Hamilton Convention Centre. Will you? #TechForGood #DrugDevelopment #AIForImpact #NGBideas #NGBiLab #NGBi2024
Excited about advancing open science, data, and technology for public good? Astera Institute has launched a fully funded, one-year residency program for scientists, engineers, and innovators to create impactful public goods. With guidance from team members like Conscience board member John Wilbanks, residents will work from Emeryville, CA, with salaries of $125,000-$250,000 and resources to tackle critical societal challenges through open science and technology. Apply by November 22! #OpenScience #PublicGood #Innovation #ScienceResidency #DataScience
Today, Astera is opening a call for its first major science residency program, a one-year, fully funded program centered on the creation of public goods. Over the course of the next 12 months, we expect to invite approximately 20 residents to join us in Emeryville, California, where we are building a hub for open science, data and technology. We will provide residents a salary of $125,000-$250,000, commensurate with experience, to explore an important problem of their choosing, along with the opportunity to pitch an additional budget for a team and other operational expenses; a chance to pitch us and others in our network for longer-term, larger-scale support; and access to substantial compute and programmatic resources. We believe that openness is the key to faster, cheaper, and better innovation, and that many public goods with the potential to broadly increase human flourishing are systematically under-produced by government, academia, and markets. We want to help address these gaps by seeding and supporting a vibrant ecosystem of mission-driven, open projects that can catalyze further private and public sector advancements. We support creative, high-agency scientists, engineers and entrepreneurs who are passionate about reducing the barriers to progress within and across domains. The central organizing principle of the residency is an unwavering commitment to leveraging open science and non-proprietary technology for the public benefit. We recognize that not all problems can be addressed by the creation of public goods, and not all projects can be scaled without proprietary IP. With our residency program, we are simply choosing to focus on the aspects or stages of the vast set of problems facing humanity that can be addressed by such means. Key constraints for our residencies include: -Open-first: Projects must yield public (open, accessible, nonproprietary) products and research that are unlikely to be created otherwise. -High-impact: They must have line of sight to generating positive impact on a societal scale (though additional years of work and funding might be necessary). We particularly like projects that have the potential to catalyze government or market funding in new directions. -“No secret sauce”: Residents must be enthusiastic about openness not only on the project level but on the metascience level, which means making it easy for others to learn both positive and negative lessons from their work. -Future-focused: Our view is that we are approaching a technological discontinuity, and we prefer projects that will leverage the resulting opportunities or create new ones. Go to our website to read more about the program and to apply before November 22 https://lnkd.in/griJDJnQ
Want to meet our CEO, Ryan Merkley, and learn more about the work we do at Conscience? Don't miss this fantastic networking opportunity for Canada's Life Sciences community on November 12! #NGBi2024 #NextGreatBigIdeas #LifeSciences #Innovation #OpenScience #DrugDiscovery #Leadership
Join Wendy Hurlburt of Life Sciences BC from the City of Vancouver, Ryan Merkley of Conscience in Ville de Montréal and Dr. Christine Allen of Intrepid Labs in the City of Toronto at the #NGBiSummit on Tuesday November 12 to learn about the #NextGreatBigIdeas in #Canadian #DrugDiscovery. For more details and to purchase tickets please go to www.NextGreatBigIdeas.com | #Biotech #Biomanufacturing #CGT #ClinicalTrials #DrugDisovery #FemTech #Healthtech #IGT #ImageGuidedTherapy #Innovation #LifeSciences #Medtech #Radiopharmaceuticals
Conscience reposted this
📢 Applications for the next round of review closes on November 22! Calling Canadian life sciences & health tech companies to apply to pitch in person to global #investors at the 2025 OBIO® Investment Summit! 👋🏽If you are a Canadian life sciences or health tech company commercializing products and services in therapeutics, medical devices, diagnostics, digital health, and health IT, this is an amazing opportunity to pitch your innovations in Toronto! ✏️https://lnkd.in/gJgg3VMt AGE-WELL NCE Inc., Altitude Accelerator, BioAlberta, BIOQuebec, BIOTECanada, Brock University, CAN Health Network , Circle Innovation, Communitech, Conscience, CQDM, Health Technology Catalyst | CTS, Canadian Venture Capital & Private Equity Association (CVCA), District 3 Innovation, Edmonton Global, Global Startups, Innovation Factory , Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada, Invest Ottawa, Invest Nova Scotia, JLABS, Life Sciences BC, Life Sciences Ontario, L-SPARK Startup Accelerator 🇨🇦, MaRS Discovery District, Medtech Canada, Medical Innovation Xchange , Montréal InVivo, National Research Council Canada / Conseil national de recherches Canada, Ontario Centre of Innovation, Synapse Life Science Consortium, Toronto Region Board of Trade, TIAP - Toronto Innovation Acceleration Partners, Velocity #OBIO #OBIOInvestmentSummit #OBIOInvestmentSummit2025 #OBIOInvestmentSummit25 #OIS2025 #OIS #healthscience #innovations #medtech #healthtech #lifesciences #callforapplications #innovationsinhealthcare #therapeutics #medicaldevices #medicaldevice #diagnostics #digitalhealth
Conscience reposted this
How can #MachineLearning be applied to #DrugDiscovery? Associate Professor David Koes and PhD candidate Ian Dunn used GNINA, a machine learning method developed in their lab, to identify potential coronavirus drugs. “I think one of the important things is we used what our tools said were the best compounds, as opposed to having a human expert come in and cherry pick which ones they think are the best,” Koes said. This work was part of the second global CACHE Challenge, which tasks scientists with predicting molecules that bind to disease-associated protein targets. Koes and Dunn earned the second highest score in the challenge. 📰 Read more: https://lnkd.in/dKmwKN2c
Don't miss our CEO Ryan Merkley speaking at the Next Great Big Ideas (NGBi) Summit on November 12! He'll be sharing insights on the work we do at Conscience alongside other leaders and innovators shaping Canada's Life Sciences community. As a bonus, all proceeds from the event will support McMaster Children’s Hospital! #NGBi2024 #LifeSciences #Innovation #OpenScience #DrugDiscovery #Leadership
Join us at the Next Great Big Ideas (NGBi) Summit on November 12th, 2024! This one-day event brings together leaders, innovators, and disruptors from across Canada's Life Sciences community. 💡 Get insights on the latest developments in the sector 🌍 Network with industry leaders and startups shaping the future 🎟 Support a great cause—fundraising for McMaster Children’s Hospital Secure your spot now and be part of the conversation! #NGBi2024 #NGBideas #NGBiLab #LifeSciences #Innovation
Conscience reposted this
[#Research] We are proud to be sharing our work on the fourth #CACHE (Critical Assessment of Computational Hit Finding Experiments) challenge, organized by Conscience targeting the TKB domain of the E3 ubiquitin-protein ligase #CBLB. As with the previous challenges, we once again used this as an opportunity to try new #methodologies and developed a new automated workflow. From retrospective benchmarking using our #docking program #Fitted to #moleculardynamics simulations and compound selection, we only relied on the results obtained from the software used. We feel very proud to be continuing to participate in #openscience; learn more about our work here: https://lnkd.in/ejBJYdFZ #openaccess #CACHEChallenge Cc: @Structural Genomics Consortium, @ISED
We're so excited see the 2024 Nobel Prizes in Chemistry and Physics recognize groundbreaking advances in drug discovery and AI that are crucial to our mission. These discoveries, which relied on high-quality, open data, exemplify the importance of both quality and openness of data for the future of AI in drug development. At Conscience, we see immense potential for innovation that benefits everyone in healthcare, and we believe that sharing data, creating benchmarks, and fostering a culture of open science and collaboration are key to accelerating drug discovery. Read more about the award-winning achievements and their implications for the the work we do: https://lnkd.in/dG-cw2zf #NobelPrize #DrugDiscovery #OpenScience #ArtificialIntelligence #Collaboration #Innovation #Conscience
Conscience reposted this
Today the entire #OpenScience community is celebrating! Congratulations to The Nobel Prize winners in Chemistry, Demis Hassabis, John Jumper and David Baker! Did you know that they had all participated in John Moult's CASP challenges? https://lnkd.in/dAayieCf #NobelPrizeChemistry #DeepMind #AlphaFold #ProteinStuctures
Conscience reposted this
How can #MachineLearning be applied to #DrugDiscovery? Associate Professor David Koes and PhD candidate Ian Dunn used GNINA, a machine learning method developed in their lab, to identify potential coronavirus drugs. “I think one of the important things is we used what our tools said were the best compounds, as opposed to having a human expert come in and cherry pick which ones they think are the best,” Koes said. This work was part of the second global CACHE Challenge, which tasks scientists with predicting molecules that bind to disease-associated protein targets. Koes and Dunn earned the second highest score in the challenge. 📰 Read more: https://lnkd.in/dKmwKN2c